Groupe Parima
Canada 77 employees Updated 9 July 2026
Groupe Parima is a finished-dose manufacturer based in Canada. It appears in 3 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with EDE (AE) and MINSA (CR). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 25 August 2023 as VAI.
3
registered plants
1 with an FDA FEI number
3
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 25 August 2023 VAI US FDA
- 24 January 2020 VAI US FDA
- 27 April 2018 VAI US FDA
- 22 January 2016 NAI US FDA
- 30 August 2013 NAI US FDA
- 13 September 2011 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Montreal, United Arab Emirates | Not on file |
| QUEBEC, Canada | Not on file |
| Canada, Canada | 3003773810 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| EDE (AE) | 2 | None |
| MINSA (CR) | 1 | None |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Groupe Parima comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 25 August 2023.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates